The credit bonds of Longfor (00960) maturing within the year have all been fully repaid on schedule.
Longhu's credit bonds maturing this year have all been fully repaid.
On August 5th, it was reported that Longfor (00960) had transferred around 950 million RMB into a special account for the redemption of "20 Longfor 06" which was due on August 7th.
Public information shows that "20 Longfor 06" had an issue date on August 7, 2020, a maturity period of 7 (5+2) years, an issuance size of 1 billion RMB, and an interest rate of 4.3%. According to the results of investor put options, Longfor's total redemption amount this time amounted to 950.44 million RMB, including principal of 907.44 million RMB and interest of 43 million RMB.
LONGFOR GROUP has already redeemed multiple domestic public bonds on schedule this year. Since the second half of the year, LONGFOR GROUP redeemed "22 Longfor 04" on July 3rd with a total of 1.766 billion RMB in principal and interest; on July 11th, Longfor transferred 522.5 million RMB for the redemption of "20 Longfor Expansion MTN001B" due on July 15th.
After the redemption of "20 Longfor 06," Longfor has redeemed over 10 billion RMB worth of public bonds this year, with all credit bonds due this year now fully repaid.
Related Articles

Jiangsu Sinopep-Allsino Biopharmaceutical (688076.SH) passed the drug cGMP on-site inspection.

BP p.l.c. Sponsored ADR (BP.US) exceeded earnings expectations in Q2. The new chairman will lead reforms and launch a comprehensive review of the business.

HK Stock Market Move | JUNSHI BIO (01877) rose nearly 35% in the final trading session. The company had previously raised over 1 billion for research and development of PD-1/VEGF bispecific antibodies, among other projects.
Jiangsu Sinopep-Allsino Biopharmaceutical (688076.SH) passed the drug cGMP on-site inspection.

BP p.l.c. Sponsored ADR (BP.US) exceeded earnings expectations in Q2. The new chairman will lead reforms and launch a comprehensive review of the business.

HK Stock Market Move | JUNSHI BIO (01877) rose nearly 35% in the final trading session. The company had previously raised over 1 billion for research and development of PD-1/VEGF bispecific antibodies, among other projects.

RECOMMEND

EU Defers Two Retaliatory Measures Against U.S. Tariffs by Six Months to Facilitate Trade Negotiations
05/08/2025

July Special Bond Issuance Reaches Year-to-Date Peak, Poised to Reinforce Infrastructure Investment
05/08/2025

Inbound Tourism Accelerates as China’s Travel Service Exports Jump Nearly 70% in H1
05/08/2025